Cisplatin‐based Chemotherapy does not Eliminate the Risk of a Second Testicular Cancer
- 1 May 1989
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 63 (5) , 531-534
- https://doi.org/10.1111/j.1464-410x.1989.tb05951.x
Abstract
Summary— Of 781 patients with germ cell cancer, 14 developed a second (subsequent) testicular cancer during follow-up. The incidence was not related to the treatment of the first germ cell cancer. In particular, adequate cisplatin-based chemotherapy did not reduce the risk of developing a second tumour. Screening programmes in patients with previous germ cell tumours should include all patients, irrespective of prior treatment.This publication has 19 references indexed in Scilit:
- Testicular cancer in young norwegiansJournal of Surgical Oncology, 1988
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- CARCINOMA-IN-SITU TESTIS IN PATIENTS WITH ASSUMED EXTRAGONADAL GERM-CELL TUMOURSThe Lancet, 1987
- Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.BMJ, 1986
- RADIATION TREATMENT OF CARCINOMA-IN-SITU OF TESTISThe Lancet, 1986
- Bilateral Malignant Testicular Germ Cell CancerBritish Journal of Urology, 1986
- CARCINOMA-IN-SITU OF TESTIS ERADICATED BY CHEMOTHERAPYThe Lancet, 1985
- Spermatogenesis and Hormonal Status after Orchiectomy for Cancer and before Supplementary TreatmentEuropean Urology, 1984
- Non‐seminoma Germ Cell Tumours (Malignant Teratoma) of the Testis Results of Treatment and an Analysis of Prognostc Factors*British Journal of Urology, 1981